Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Cross Above Fifty Day Moving Average – What’s Next?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $14.86 and traded as high as $15.00. Ono Pharmaceutical shares last traded at $15.00, with a volume of 288 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, Ono Pharmaceutical currently has an average rating of “Hold”.

Ono Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.86 and a current ratio of 3.28. The stock has a 50 day moving average of $14.86 and a 200 day moving average of $14.72. The stock has a market capitalization of $7.05 billion, a P/E ratio of 14.29 and a beta of 0.33.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.